Brazilian Scientist Develops Nanotechnology That Could Transform Treatment of Cancer and Inflammatory Diseases
A breakthrough developed in Brazil may open a new chapter in the treatment of cancer and several other serious diseases affecting millions of people worldwide.
Led by Brazilian physician and researcher Raul Cavalcante Maranhão, a team of scientists at the Faculty of Medicine of the University of São Paulo has created an innovative therapeutic platform based on microscopic particles capable of transporting powerful medications directly to diseased tissues in the body.
The technology, known as LDE nanoparticles, works like a “smart delivery system” for drugs, allowing treatments to reach tumors and inflamed tissues with greater precision while dramatically reducing the toxic side effects commonly associated with chemotherapy.
The discovery is rooted in nanotechnology. The researchers developed extremely small particles composed mainly of cholesterol that mimic LDL, the natural molecule responsible for carrying cholesterol through the bloodstream.
Because of this similarity, the particles—named LDE—are easily absorbed by cells with high metabolic activity, such as cancer cells or inflamed tissues.
Once injected into the bloodstream, these nanoparticles act as carriers for chemotherapy drugs. They travel through the body and concentrate the medication precisely where it is needed, minimizing damage to healthy organs and tissues.
According to the research team, this approach can significantly improve the safety and effectiveness of treatments that were previously limited by their high toxicity.
Promising Results in Cancer Treatment
Several well-known chemotherapy drugs have already been tested using the LDE platform, including paclitaxel, docetaxel, methotrexate and daunorubicin.
In experimental studies involving animals, the results were striking. Compared to conventional chemotherapy formulations, the LDE-based treatments demonstrated as dramatically reduced toxicity; greater anti-tumor effectiveness; improved tolerance to treatment; increased survival rates.
Early clinical studies with patients suffering from advanced or metastatic cancers—including breast, ovarian, prostate and lung tumors—also revealed encouraging results.
Many of these patients were too fragile to undergo traditional chemotherapy and had been scheduled only for palliative care. Yet treatments using the LDE platform showed remarkable safety and signs of clinical benefit.
One pilot study focused on patients with acute myeloid leukemia undergoing bone marrow transplantation—one of the most aggressive and challenging treatments in oncology.
Using an LDE-based formulation of the drug etoposide as part of the transplant therapy, researchers observed notable outcomes: the two-year survival rate was three times higher than expected, and none of the patients experienced acute transplant rejection or severe treatment-related toxicity.
Although the number of participants was small, the results drew attention within the scientific community.
One of the most surprising aspects of the discovery is that the technology may extend far beyond oncology.
Because the LDE nanoparticles dramatically reduce the toxicity of chemotherapy drugs, researchers began exploring whether these powerful medications could be used to treat other diseases when delivered through this system.
Experimental studies have already shown promising results in conditions such as:
atherosclerosis, the buildup of plaque in arteries, as arthritis and inflammatory; diseases; heart attacks; transplant rejection; sépsis; aneurysms associated with Marfan syndrome; stroke and and difficult surgical wounds.
In several experimental models, the treatments reduced inflammation, improved heart function and even prevented the development of vascular complications.
From Laboratory to Real-World Medicine
Clinical pilot studies have also been conducted in patients with cardiovascular disease and endometriosis, showing excellent safety and encouraging therapeutic responses.
Another critical step has already been achieved: the technology required to manufacture the LDE-based formulations at larger scale has been developed and validated. This paves the way for large-scale clinical trials and eventual industrial production.
Importantly, researchers believe the cost of the therapy may remain comparable to existing treatments, potentially making it accessible for public health systems such as Brazil’s SUS.
For Professor Raul Cavalcante Maranhão, the work represents decades of research in nanotechnology applied to medicine. If confirmed in larger clinical trials, the LDE platform could redefine how powerful drugs are delivered within the human body—making treatments more precise, safer and potentially more effective for a wide range of diseases.
